Revvity Q4 Earnings Call Highlights

Core Insights - Revvity reported stronger-than-expected performance in diagnostics and life sciences, with fourth-quarter revenue exceeding expectations [2][5][6] Financial Performance - Fourth-quarter revenue reached $772 million, reflecting 4% organic growth and approximately 2% foreign-exchange tailwind [4] - Full-year revenue totaled $2.86 billion, with 3% organic growth and a 1% FX tailwind; adjusted operating margin was 27.1%, down 120 basis points year-over-year [3] - Adjusted EPS for the full year was $5.06, up 3% year-over-year, exceeding initial guidance [3] Segment Performance - Diagnostics segment revenue was $390 million, up 7% organically, while life sciences segment revenue was $382 million, flat organically [2] - Reproductive Health and Immunodiagnostics grew mid-single digits and high single digits, respectively, with notable contributions from newborn screening and Genomics England [1] Capital Deployment - Revvity repurchased over $800 million of shares in 2025, reducing share count by 8.5 million shares [8] - Free cash flow for the fourth quarter was $162 million, bringing full-year free cash flow to $515 million, with a conversion rate of 84% [9] 2026 Guidance - Management provided an initial 2026 outlook of $2.96 billion to $2.99 billion in revenue, with expected organic growth of 2% to 3% [10] - Adjusted EPS guidance for 2026 is set at $5.35 to $5.45, assuming an 18% adjusted tax rate and approximately $95 million in net interest and other expenses [11] Strategic Initiatives - The company is focusing on software and AI initiatives, including the launch of Signals Xynthetica, aimed at accelerating drug development [13] - Revvity remains disciplined on M&A, primarily targeting software and life sciences reagents [15]